Terumo Neuro
Carsten Schroeder joined MicroVention as President and CEO in November of 2020. Mr. Schroeder has more than 25 years of senior executive experience across pharmaceuticals, medical devices, and in-vitro diagnostics. Prior to MicroVention, he was President and CEO of Grifols Diagnostic Solutions, (joining Grifols through the acquisition of Novartis Diagnostics). He was the also the President of the Diagnostic Business Unit and the Site Head for Novartis in Emeryville, CA. Before Novartis, he held various Vice President positions at Boston Scientific for nine years and was based in France, Germany, and the United States. During this time, he was responsible for the neurovascular business. Mr. Schroeder speaks several languages and has lived in over 10 countries throughout his career.
Mr. Schroeder earned his Bachelor of Arts in Economics from the University of Cologne in Germany and a Master of Business from the European School of Management in Paris (ESCP).
This person is not in any offices
Terumo Neuro
1 followers
A global leader in neurovascular innovation, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.